Farallon Capital Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Farallon Capital Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-308,260	Closed	-$30.8M	–	97
2018 Q1	$30.8M	Buy	308,260 +18,260	+6%	+$1.97M	0.21%	58
2017 Q4	$27.2M	Buy	290,000 +53,784	+23%	+$5.09M	0.22%	51
2017 Q3	$24M	Buy	+236,216	New	+$20.6M	0.21%	52
2017 Q2	–	Sell	-120,000	Closed	-$10.3M	–	85
2017 Q1	$10.3M	Buy	120,000 +29,045	+32%	+$2.09M	0.11%	60
2016 Q4	$5.84M	Buy	+90,955	New	+$5.6M	0.07%	61

Other funds holding LKFT

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Farallon Capital Management's LKFT Position: Q2 2018 in Review

Farallon Capital Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2018, closing a stake of 308,260 shares — an estimated $30.8M sold.

Farallon Capital Management first reported a position in LKFT in Q4 2016 and held it in 5 quarters. The position peaked at $30.8M in Q1 2018. 79 funds tracked by Wall St. Rank hold LKFT as of Q2 2018.

Farallon Capital Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2018 after selling out during the quarter.
Farallon Capital Management sold 308,260 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2018, an estimated $30.8M.
Farallon Capital Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2016 and held it in 5 quarters.
Farallon Capital Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $30.8M in Q1 2018.
79 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2018.

Based on Farallon Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.